https://scholars.lib.ntu.edu.tw/handle/123456789/521075
標題: | The Relationships of Obesity-Related Genetic Variants with Metabolic Profiles and Response to Metformin in Clozapine-Treated Patients with Schizophrenia | 作者: | Chen P.-Y. Lu M.-L. Huang M.-C. Kao C.-F. PO-HSIU KUO Chiu C.-C. Lin S.-K. HSIU-PO KUO |
公開日期: | 2015 | 出版社: | Lippincott Williams and Wilkins | 卷: | 35 | 期: | 5 | 起(迄)頁: | 574-578 | 來源出版物: | Journal of Clinical Psychopharmacology | 摘要: | Obesity-related genetic variants, including TMEM18 (rs6548238), SH2B1 (rs7498665), and GNPDA2 (rs10938397), have been shown to be associated with obesity in the general population. Our study aimed to test whether these genetic variants are associated with metabolic profiles and metformin treatment response in clozapine-treated schizophrenic patients. We recruited 107 clozapine-treated patients who were genotyped and measured their metabolic profiles. Fifty-five subjects, who had at least 1 metabolic abnormality in a range of measures, were subsequently randomized to a 24-week trial of metformin (n = 28) or placebo (n = 27). We examined the associations between TMEM18, SH2B1, GNPDA2 genetic variants and metabolic profiles at baseline in all patients and metabolic changes in the trial groups. We found a significant association between SH2B1 and blood pressure at baseline in all patients. In the metformin group, TMEM18 minor allele carriers had a greater reduction in insulin levels (P = 0.04). A significantly higher proportion of TMEM18 and GNPDA2 minor allele carriers (60% and 40%) lost more than 7% of their body weight after metformin treatment as compared with their homozygous counterparts (21.7% and 15.4%, P = 0.02 and 0.004, respectively). There were trends toward favorable metabolic changes in minor allele carrier groups. In the placebo group, no association between genetic variants and changes in metabolic profiles was found. In conclusion, the study results suggest that these genes might be associated with metabolic abnormalities and response to metformin in clozapine-treated patients with schizophrenia. ? 2015 Wolters Kluwer Health, Inc. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84941282598&doi=10.1097%2fJCP.0000000000000386&partnerID=40&md5=5ed3ad27a5410fc21d14d1c93162aba5 https://scholars.lib.ntu.edu.tw/handle/123456789/521075 |
ISSN: | 0271-0749 | DOI: | 10.1097/JCP.0000000000000386 | SDG/關鍵字: | clozapine; insulin; metformin; placebo; clozapine; glucosamine-6-phosphate isomerase; isomerase; membrane protein; metformin; neuroleptic agent; SH2B1 protein, human; signal transducing adaptor protein; TMEM18 protein, human; adult; aged; allele; Article; blood pressure; body weight; controlled study; correlation analysis; double blind procedure; female; gene; genetic association; genetic variability; genotype; GNPDA2 gene; human; insulin blood level; major clinical study; male; metabolic disorder; metabolism; obesity; priority journal; randomized controlled trial; schizophrenia; SH2B1 gene; statistical analysis; TMEM18 gene; treatment response; chemically induced; genetic predisposition; genetic variation; genetics; Metabolic Diseases; middle aged; obesity; schizophrenia; Adaptor Proteins, Signal Transducing; Adult; Aldose-Ketose Isomerases; Alleles; Antipsychotic Agents; Clozapine; Double-Blind Method; Female; Genetic Predisposition to Disease; Genetic Variation; Genotype; Humans; Male; Membrane Proteins; Metabolic Diseases; Metformin; Middle Aged; Obesity; Schizophrenia |
顯示於: | 流行病學與預防醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。